Apoptosis 17 (11), 11561169 (2012)
All three doses of orforglipron (6 mg, 12 mg, and 36 mg) met the primary and all key secondary endpoints by showing significant weight loss, meaningful A1C reductions, and improvements in cardiometabolic risk factors compared with placebo at 72 weeks
The same core protocols apply, but pay particular attention to protein intake and muscle preservation, as the accelerated weight loss increases lean mass loss risk proportionally
The peptide shows varying effectiveness depending on the underlying cause of your symptoms
Patients may want to confirm that their physicians office and pharmacy understand this step, since skipping it or processing the prescription incorrectly could potentially delay access to the program
doi: 10.1080/01635581.2010.509534 336 HuiCQiXQianyongZXiaoliPJundongZMantianM